Lobelia chinensis Lour inhibits the progression of hepatocellular carcinoma via the regulation of the PTEN/AKT signaling pathway in vivo and in vitro.

Autor: Luo J; The First Affiliated Hospital of Sun Yat-sen, Department of Traditional Chinese Medicine, Guangzhou, 510800, China; Shenzhen Children's Hospital, Futian District, Shenzhen, 518000, Guangdong, PR China., Chen QX; The First Affiliated Hospital of Sun Yat-sen, Department of Traditional Chinese Medicine, Guangzhou, 510800, China., Li P; Department of Radiotherapy, The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Zhengzhou, 450003, China., Yu H; The First Affiliated Hospital of Sun Yat-sen, Department of Traditional Chinese Medicine, Guangzhou, 510800, China., Yu L; The First Affiliated Hospital of Sun Yat-sen, Department of Traditional Chinese Medicine, Guangzhou, 510800, China., Lu JL; Department of General Practice, Shenzhen Longgang Fourth People's Hospital, Shenzhen, 518100, China., Yin HZ; Department of Pediatrics, Beijing University of Chinese Medicine Shenzhen Hospital (Longgang), Shenzhen, 518100, China., Huang BJ; State Key Laboratory of Oncology in South China, Sun Yat-sen University Cancer Center, Department of Experimental Research, Collaborative Innovation Center for Cancer Medicine, Guangzhou, 510060, China. Electronic address: huangbj@sysucc.org.cn., Zhang SJ; The First Affiliated Hospital of Sun Yat-sen, Department of Traditional Chinese Medicine, Guangzhou, 510800, China. Electronic address: zhshjun@mail.sysu.edu.cn.
Jazyk: angličtina
Zdroj: Journal of ethnopharmacology [J Ethnopharmacol] 2024 Jan 10; Vol. 318 (Pt A), pp. 116886. Date of Electronic Publication: 2023 Jul 08.
DOI: 10.1016/j.jep.2023.116886
Abstrakt: Ethnopharmacological Relevance: Lobelia chinensis Lour. (LCL) is a common herb used for clearing heat and detoxifying, and it has antitumor activity. Quercetin is one of its important components, which may play an important role in the treatment of hepatocellular carcinoma (HCC).
Aim of the Study: To study the active ingredients of LCL, their mechanism of action on HCC, and lay the foundations for the development of new drugs for the treatment of HCC.
Materials and Methods: Network pharmacology was used to examine the probable active ingredients and mechanisms of action of LCL in HCC treatment. Based on an oral bioavailability of ≥30% and a drug-likeness index of ≥0.18, relevant compounds were selected from the Traditional Chinese Medicine Systems Pharmacology database and TCM Database@Taiwan. HCC-related targets were identified using gene cards and the Online Mendelian Inheritance in Man (OMIM) database. A Venn diagram was created to assess the relationship between the intersection of disease and medication targets by creating a protein-protein interaction network, and the hub targets were selected by topology. Gene Ontology enrichment analyses were performed using the DAVID tool. Finally, in vivo and in vitro experiments (qRT-PCR, western blotting, hematoxylin and eosin staining, transwell assays, scratch tests, and flow cytometry assays) verified that LCL demonstrated notable therapeutic effects on HCC.
Results: In total, 16 bioactive LCL compounds met the screening criteria. The 30 most important LCL therapeutic target genes were identified. Of these, AKT1 and MAPK1 were the most important target genes, and the AKT signaling pathway was identified as the key pathway. Transwell and scratch assays showed that LCL prevented cell migration, and flow cytometry tests revealed that the LCL-treated group showed a considerably higher rate of apoptosis than the control group. LCL reduced tumor formation in mice in vivo, and Western blot analysis of tumor tissues treated with LCL indicated variations in PTEN, p-MAPK and p-AKT1 levels. The results show that LCL may inhibit the progression of HCC through the PTEN/AKT signaling pathway to achieve the goal of treating HCC.
Conclusion: LCL is a broad-spectrum anticancer agent. These findings reveal potential treatment targets and strategies for preventing the spread of cancer, which could aid in screening potential traditional Chinese medicine for anticancer and clarifying their mechanisms.
Competing Interests: Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
(Copyright © 2023 The Authors. Published by Elsevier B.V. All rights reserved.)
Databáze: MEDLINE
Externí odkaz: